Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Lithocholic Acid, a Metabolite of the Microbiome, Increases Oxidative Stress in Breast Cancer.

Kovács P, Csonka T, Kovács T, Sári Z, Ujlaki G, Sipos A, Karányi Z, Szeőcs D, Hegedűs C, Uray K, Jankó L, Kiss M, Kiss B, Laoui D, Virág L, Méhes G, Bai P, Mikó E.

Cancers (Basel). 2019 Aug 27;11(9). pii: E1255. doi: 10.3390/cancers11091255.

2.

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.

Newton JM, Hanoteau A, Liu HC, Gaspero A, Parikh F, Gartrell-Corrado RD, Hart TD, Laoui D, Van Ginderachter JA, Dharmaraj N, Spanos WC, Saenger Y, Young S, Sikora AG.

J Immunother Cancer. 2019 Aug 13;7(1):216. doi: 10.1186/s40425-019-0698-6.

3.

High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity.

Willebrand R, Hamad I, Van Zeebroeck L, Kiss M, Bruderek K, Geuzens A, Swinnen D, Côrte-Real BF, Markó L, Lebegge E, Laoui D, Kemna J, Kammertoens T, Brandau S, Van Ginderachter JA, Kleinewietfeld M.

Front Immunol. 2019 Jun 4;10:1141. doi: 10.3389/fimmu.2019.01141. eCollection 2019.

4.

Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A's: Abundance, Activation and Antigen-Delivery.

Murgaski A, Bardet PMR, Arnouk SM, Clappaert EJ, Laoui D.

Cancers (Basel). 2019 May 14;11(5). pii: E670. doi: 10.3390/cancers11050670. Review.

5.

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages.

Xavier C, Blykers A, Laoui D, Bolli E, Vaneyken I, Bridoux J, Baudhuin H, Raes G, Everaert H, Movahedi K, Van Ginderachter JA, Devoogdt N, Caveliers V, Lahoutte T, Keyaerts M.

Mol Imaging Biol. 2019 Oct;21(5):898-906. doi: 10.1007/s11307-018-01302-5.

PMID:
30671739
6.

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.

J Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9.

7.

Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.

Clappaert EJ, Murgaski A, Van Damme H, Kiss M, Laoui D.

Front Immunol. 2018 Oct 8;9:2250. doi: 10.3389/fimmu.2018.02250. eCollection 2018. Review.

8.

Myeloid cell heterogeneity in cancer: not a single cell alike.

Kiss M, Van Gassen S, Movahedi K, Saeys Y, Laoui D.

Cell Immunol. 2018 Aug;330:188-201. doi: 10.1016/j.cellimm.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29482836
9.

Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.

Bonelli S, Geeraerts X, Bolli E, Keirsse J, Kiss M, Pombo Antunes AR, Van Damme H, De Vlaminck K, Movahedi K, Laoui D, Raes G, Van Ginderachter JA.

FEBS J. 2018 Feb;285(4):777-787. doi: 10.1111/febs.14202. Epub 2017 Sep 6. Review.

10.

CCR2-dependent monocyte-derived macrophages resolve inflammation and restore gut motility in postoperative ileus.

Farro G, Stakenborg M, Gomez-Pinilla PJ, Labeeuw E, Goverse G, Di Giovangiulio M, Stakenborg N, Meroni E, D'Errico F, Elkrim Y, Laoui D, Lisowski ZM, Sauter KA, Hume DA, Van Ginderachter JA, Boeckxstaens GE, Matteoli G.

Gut. 2017 Dec;66(12):2098-2109. doi: 10.1136/gutjnl-2016-313144. Epub 2017 Jun 14. Erratum in: Gut. 2019 Sep;68(9):1726.

11.

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, De Palma M.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaak9670. doi: 10.1126/scitranslmed.aak9670.

PMID:
28404865
12.

Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies.

Keirsse J, Van Damme H, Van Ginderachter JA, Laoui D.

J Leukoc Biol. 2017 Aug;102(2):317-324. doi: 10.1189/jlb.4MR1116-466R. Epub 2017 Apr 7. Review.

PMID:
28389620
13.

The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.

Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, Kiss M, Bolli E, Lahmar Q, Sichien D, Serneels J, Scott CL, Boon L, De Baetselier P, Mazzone M, Guilliams M, Van Ginderachter JA.

Nat Commun. 2016 Dec 23;7:13720. doi: 10.1038/ncomms13720.

14.

Novel insights in the regulation and function of macrophages in the tumor microenvironment.

Bolli E, Movahedi K, Laoui D, Van Ginderachter JA.

Curr Opin Oncol. 2017 Jan;29(1):55-61. Review.

PMID:
27792052
15.

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.

Baer C, Squadrito ML, Laoui D, Thompson D, Hansen SK, Kiialainen A, Hoves S, Ries CH, Ooi CH, De Palma M.

Nat Cell Biol. 2016 Jul;18(7):790-802. doi: 10.1038/ncb3371. Epub 2016 Jun 13.

PMID:
27295554
16.

M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment.

Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, Vereecke L, Tacke F, De Baetselier P, Van Ginderachter JA, Laoui D.

Cancer Res. 2016 Jan 1;76(1):35-42. doi: 10.1158/0008-5472.CAN-15-0869. Epub 2015 Nov 16.

17.

E-cadherin expression in macrophages dampens their inflammatory responsiveness in vitro, but does not modulate M2-regulated pathologies in vivo.

Van den Bossche J, Laoui D, Naessens T, Smits HH, Hokke CH, Stijlemans B, Grooten J, De Baetselier P, Van Ginderachter JA.

Sci Rep. 2015 Jul 31;5:12599. doi: 10.1038/srep12599.

18.

Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment.

Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA.

Biochim Biophys Acta. 2016 Jan;1865(1):23-34. doi: 10.1016/j.bbcan.2015.06.009. Epub 2015 Jul 2. Review.

PMID:
26145884
19.

PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments.

Blykers A, Schoonooghe S, Xavier C, D'hoe K, Laoui D, D'Huyvetter M, Vaneycken I, Cleeren F, Bormans G, Heemskerk J, Raes G, De Baetselier P, Lahoutte T, Devoogdt N, Van Ginderachter JA, Caveliers V.

J Nucl Med. 2015 Aug;56(8):1265-71. doi: 10.2967/jnumed.115.156828. Epub 2015 Jun 11.

20.

Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages.

Morias Y, Abels C, Laoui D, Van Overmeire E, Guilliams M, Schouppe E, Tacke F, deVries CJ, De Baetselier P, Beschin A.

PLoS Pathog. 2015 May 28;11(5):e1004873. doi: 10.1371/journal.ppat.1004873. eCollection 2015 May.

21.

Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression.

Chittezhath M, Dhillon MK, Lim JY, Laoui D, Shalova IN, Teo YL, Chen J, Kamaraj R, Raman L, Lum J, Thamboo TP, Chiong E, Zolezzi F, Yang H, Van Ginderachter JA, Poidinger M, Wong AS, Biswas SK.

Immunity. 2014 Nov 20;41(5):815-29. doi: 10.1016/j.immuni.2014.09.014. Epub 2014 Oct 30.

22.

Targeting cell-intrinsic and cell-extrinsic mechanisms of intravasation in invasive breast cancer.

Keirsse J, Laoui D, Van Overmeire E, Van Ginderachter JA.

Sci Signal. 2014 Nov 25;7(353):pe28. doi: 10.1126/scisignal.aaa2104.

PMID:
25429075
23.

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression.

Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G.

Front Immunol. 2014 Oct 7;5:489. doi: 10.3389/fimmu.2014.00489. eCollection 2014. Review.

24.

STAT of the union: dynamics of distinct tumor-associated macrophage subsets governed by STAT1.

Van Overmeire E, Laoui D, Keirsse J, Bonelli S, Lahmar Q, Van Ginderachter JA.

Eur J Immunol. 2014 Aug;44(8):2238-42. doi: 10.1002/eji.201444870.

25.

Hypoxia and tumor-associated macrophages: A deadly alliance in support of tumor progression.

Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA.

Oncoimmunology. 2014 Jan 1;3(1):e27561. Epub 2014 Jan 3.

26.

Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues.

Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A.

Front Immunol. 2014 Mar 26;5:127. doi: 10.3389/fimmu.2014.00127. eCollection 2014. Review.

27.

Presence and regulation of insulin-regulated aminopeptidase in mouse macrophages.

Nikolaou A, Stijlemans B, Laoui D, Schouppe E, Tran HT, Tourwé D, Chai SY, Vanderheyden PM, Van Ginderachter JA.

J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):466-79. doi: 10.1177/1470320313507621. Epub 2014 Feb 14.

PMID:
24532823
28.

Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.

Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L, Mazzone M.

Cancer Cell. 2013 Dec 9;24(6):695-709. doi: 10.1016/j.ccr.2013.11.007.

29.

Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.

Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe E, Elkrim Y, Karroum O, Jordan B, Carmeliet P, Gysemans C, De Baetselier P, Mazzone M, Van Ginderachter JA.

Cancer Res. 2014 Jan 1;74(1):24-30. doi: 10.1158/0008-5472.CAN-13-1196. Epub 2013 Nov 12.

30.

Unsuspected allies: chemotherapy teams up with immunity to fight cancer.

Laoui D, Van Overmeire E, Van Ginderachter JA.

Eur J Immunol. 2013 Oct;43(10):2538-42. doi: 10.1002/eji.201344042.

31.

Modulation of CD8(+) T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells.

Schouppe E, Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA.

Immunobiology. 2013 Nov;218(11):1385-91. doi: 10.1016/j.imbio.2013.07.003. Epub 2013 Jul 15. Review.

PMID:
23932436
32.

Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.

Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P, Van Ginderachter JA.

Eur J Immunol. 2013 Nov;43(11):2930-42. doi: 10.1002/eji.201343349. Epub 2013 Aug 25.

33.

In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities.

Pello OM, Chèvre R, Laoui D, De Juan A, Lolo F, Andrés-Manzano MJ, Serrano M, Van Ginderachter JA, Andrés V.

PLoS One. 2012;7(9):e45399. doi: 10.1371/journal.pone.0045399. Epub 2012 Sep 20.

34.

Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer.

Schoonooghe S, Laoui D, Van Ginderachter JA, Devoogdt N, Lahoutte T, De Baetselier P, Raes G.

Immunobiology. 2012 Dec;217(12):1266-72. doi: 10.1016/j.imbio.2012.07.009. Epub 2012 Jul 21. Review.

PMID:
22884356
35.

Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.

Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, Bouwens L, Lahoutte T, De Baetselier P, Raes G, Devoogdt N, Van Ginderachter JA.

Cancer Res. 2012 Aug 15;72(16):4165-77. doi: 10.1158/0008-5472.CAN-11-2994. Epub 2012 Jun 19.

36.

Claudin-1, claudin-2 and claudin-11 genes differentially associate with distinct types of anti-inflammatory macrophages in vitro and with parasite- and tumour-elicited macrophages in vivo.

Van den Bossche J, Laoui D, Morias Y, Movahedi K, Raes G, De Baetselier P, Van Ginderachter JA.

Scand J Immunol. 2012 Jun;75(6):588-98. doi: 10.1111/j.1365-3083.2012.02689.x.

37.

Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions.

Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA.

Int J Dev Biol. 2011;55(7-9):861-7. doi: 10.1387/ijdb.113371dl. Review.

38.

Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site.

Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA.

Immunobiology. 2011 Nov;216(11):1192-202. doi: 10.1016/j.imbio.2011.06.007. Epub 2011 Jun 30. Review.

PMID:
21803441
39.

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P.

Cancer Cell. 2011 Jan 18;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009. Epub 2011 Jan 6.

40.

Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.

Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA.

Cancer Res. 2010 Jul 15;70(14):5728-39. doi: 10.1158/0008-5472.CAN-09-4672. Epub 2010 Jun 22.

Supplemental Content

Support Center